Artivion | CRY - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Abbott USD 9.31B 104M 2026-03
Accuray USD 37.18M 567K 2024-12
AngioDynamics USD 81.95M 1.68M 2025-09
Artivion USD 111.2M 9.45M 2025-12
AtriCure USD 140.72M 2.71M 2026-03
Baxter International USD 6.04B 2.85B 2026-03
Becton, Dickinson and Co. USD 24.13B 19.54B 2026-03
Boston Scientific USD 4.15B 107M 2026-03
Edwards Lifesciences USD 1.13B 65.4M 2026-03
Inogen USD 49.14M 665K 2024-09
Integra LifeSciences USD 1.04B 673.49M 2026-03
J&J USD 17.44B 1.53B 2026-03
Mesa Laboratories USD 33.98M 2.03M 2024-12
Orthofix International USD 213.79M 12.36M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
ResMed USD 925.74M 525K 2026-03
Stryker USD 4.92B 284M 2026-03
Tandem Diabetes Care USD 282.09M 9.97M 2025-12
Teleflex USD 3.08B 2.55B 2026-03
Terumo JPY 268.87B 16.12B 2026-03
Trinity Biotech USD 14.82M 7.81M 2025-09